Cystatin C is an established biomarker for renal function, and, given the close association of chronic kidney disease and cardiovascular disease might indicate new-onset or deteriorating cardiovascular disease. However, evidence for cystatin C as a predictor of cardiovascular events is limited and controversial. We therefore aimed at investigating the role of Cystatin C as a predictor of future major adverse cardiovascular events (MACE) in a high risk-cohort of patients with coronary artery disease (CAD) . Cystatin C was measured in 1098 patients with angiographically proven CAD. Vascular events were recorded over a mean follow-up of 8.0±5.0 years. At baseline, 239 patients had T2DM and 859 did not have diabetes. During follow-up, 30.0% of our patients suffered MACE. Cystatin C proved to be a strong and independent predictor of vascular events in the total study cohort (standardized adjusted HR 1.20 [1.12-1.28], p<0.001) . When diabetes status was taken into account, cystatin C significantly predicted major cardiovascular events in non T2DM patients (HR=1.16 [1.08-1.26], p<0.001) and in patients with T2DM (HR=1.34 [1.13-1.60], p=0.001) . We conclude that cystatin C predicts major cardiovascular events in patients with coronary artery disease both among patients with type 2 diabetes and in nondiabetes individuals.


A.Mader: None. C.H.Saely: None. M.Maechler: None. B.Larcher: None. L.Sprenger: None. A.Leiherer: None. A.Muendlein: None. A.Vonbank: None. H.Drexel: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at